Here, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.

中文翻译：

---

多巴胺 3 受体作为阿片类药物使用障碍的候选生物标志物和治疗方法

在这里，我们提出最近的研究表明，特定的DRD3单核苷酸多态性（SNP，例如rs324029和rs2654754）可能作为阿片类药物使用障碍（OUD）的预后生物标志物。此外，新型多巴胺 3 受体 (D3R) 部分激动剂和拮抗剂的临床前研究已被评估为候选 OUD 疗法，并显示与原始 D3R 拮抗剂相比，心血管毒性风险降低。根据这些发现，我们认为DRD3 SNP 可以作为评估 OUD 风险的诊断工具，并且需要更多的研究来检验 D3R 作为治疗 OUD 的安全有效的治疗靶点。